Comparative assessment for rat strain differences in metabolic profiles of 14 drugs in Wistar Han and Sprague Dawley hepatocytes

References

• Aouri M, Barcelo C, Ternon B, et al.; the Swiss HIV Cohort Study. (2016). In vivo profiling and distribution of known and novel phase I and phase II metabolites of efavirenz in plasma, urine, and cerebrospinal fluid. Drug Metab Dispos 44:151–61.
   PubMed Web of Science ®Google Scholar
• Dix KJ, Coleman DP, Jeffcoat AR. (1999). Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley Rats and Syrian Golden Hamsters. Drug Metab Dispos 27:138–46.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhao A, Zhou M, et al. (2011). GC/MS-based urinary metabolomics reveals systematic differences in metabolism and ethanol response between Sprague-Dawley and Wistar rats. Metabolomics 7:363–74.
   Web of Science ®Google Scholar
• Garcia-Lopez P, Pérez-Urizar J, Ibarra A, et al. (1996). Comparison between Sprague-Dawley and Wistar rats as an experimental model of pharmacokinetic alterations induced by spinal cord injury. Arch Med Res 27:453–7.
   PubMed Web of Science ®Google Scholar
• Garg R, Heinzle E, Noor F. (2018). Hepatocytes of Wistar and Sprague Dawley rats differ significantly in their central metabolism. J Cell Biochem 119:909–17.
   PubMed Web of Science ®Google Scholar
• Grimsley A, Gallagher R, Hutchison M, et al. (2013). Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam. Biochemical Pharmacology 86:529–38.
   PubMed Web of Science ®Google Scholar
• Hart SJ, Calder IC, Tange JD. (1982). The metabolism and toxicity of paracetamol in Sprague-Dawley and Wistar rats. Eur J Drug Metab Pharmacokinet 7:203–22.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJ, Houston JB, et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234.
   PubMed Web of Science ®Google Scholar
• Holmes E, Nicholls AW, Lindon JC, et al. (2000). Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Toxicol 13:471–8.
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. (2003). Identification of the Cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31: 540–7.
   PubMed Web of Science ®Google Scholar
• Iwamura A, Fukami T, Hosomi H, et al. (2011). CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos 39:838–46.
   PubMed Web of Science ®Google Scholar
• Kishida T, Muto S, Hayashi M, et al. (2008). Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J Toxicol Sci 33:447–57.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–5.
   PubMed Web of Science ®Google Scholar
• Korprasertthaworn P, Polasek TM, Sorich MJ, et al. (2015). In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism. Drug Metab Dispos 43:1806–14.
   PubMed Web of Science ®Google Scholar
• Kubatka P, Ahlersová E, Ahlers I, et al. (2002). Variability of mammary carcinogenesis induction in female Sprague-Dawley and Wistar:Han rats: the effect of season and age. Physiol Res 51:633–40.
   PubMed Web of Science ®Google Scholar
• KüHn ER, KüHn ER, Bellon K, et al. (1983). Endocrine differences between the Wistar and Sprague-Dawley laboratory rat: influence of cold adaptation. Horm Metab Res 15:491–8.
   PubMed Web of Science ®Google Scholar
• Kutsukake T, Furukawa Y, Ondo K, et al. (2019). Quantitative analysis of UDP-Glucuronosyltransferase Ugt1a and Ugt2b mRNA expression in the rat liver and small intestine: sex and strain differences. Drug Metab Dispos 47:38–44.
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Wang L, Ma X. (2011). CYP3A-Mediated Generation of Aldehyde and Hydrazine in Atazanavir Metabolism. Drug Metab Dispos 39:394–401.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos 32:1247–53.
   PubMed Web of Science ®Google Scholar
• Mulder T, Bobba S, Johnson K, et al. (2020). Bioactivation of α,β-unsaturated carboxylic acids through acyl-glucuronidation. Drug Metab Dispos.DMD-AR-2020-000096; DOI:10.1124/dmd.120.000096
   PubMed Web of Science ®Google Scholar
• Multlib AE, Chen H, Nemeth GA, et al. (1999). Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319–33.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. (2003). Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos 31:580–8.
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Nakayama SMM, Watanabe KP, et al. (2016). Strain differences in cytochrome P450 mRNA and protein expression, and enzymatic activity among Sprague Dawley, Wistar, Brown Norway and Dark Agouti rats. Toxicology J Vet Med Sci 78: 675–80.
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9.
   PubMed Web of Science ®Google Scholar
• Prakash C, Kamel A, Anderson W, Howard H. (1997). Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. Drug Metab Dispos 25: 206–18.
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, et al. (2009). Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81.
   PubMed Web of Science ®Google Scholar
• Richmond W, Wogan M, Isbell J, Gordon WP. (2010). Interstrain differences of in vitro metabolic stability and impact on early drug discovery. J Pharm Sci 99:4463–8.
   PubMed Web of Science ®Google Scholar
• Riley MGI, Castelli MC, Paehler EA. (2009). Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol 28:278–93.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, et al. (2003). The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–41.
   PubMed Web of Science ®Google Scholar
• Saito K, Sakai N, Kim H, et al. (2004). Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark agouti, and wistar strain rats. Drug Metab Dispos 32:959–65.
   PubMed Web of Science ®Google Scholar
• Sakai N, Sakamoto KQ, Fujita S, Ishizuka M. (2009). The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats. Drug Metab Dispos 37:1703–10.
   PubMed Web of Science ®Google Scholar
• Singh JK, Solanki A, Shirsath VS. (2012). Comparative in-vitro intrinsic clearance of imipramine in multiple species liver microsomes: human, rat, mouse and dog. J Drug Metab Toxicol 3:126.
   Google Scholar
• Soars MG, Burchell B, Riley RJ. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382–90.
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, Grime K, Riley RJ. (2007). The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2–15.
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Holloway MG. (2009). Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215–28.
   PubMed Web of Science ®Google Scholar
• Weber K, Razinger T, Hardisty JF, et al. (2011). Differences in rat models used in routine toxicity studies. Int J Toxicol 30:162–73.
   PubMed Web of Science ®Google Scholar
• Wempe MF, Wacher VJ, Ruble KM, et al. (2008). Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. Int J Pharm 346:25–37.
   PubMed Web of Science ®Google Scholar
• Wiśniewski JR, Hein MY, Cox J, Mann M. (2014). A “proteomic ruler” for protein copy number and concentration estimation without spike-in standards. Mol Cell Proteomics 13:3497–4506.
   PubMed Web of Science ®Google Scholar
• Zhang D, He K, Raghavan N, et al. (2009). Comparative metabolism of C-14 apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37:1738–48.
   PubMed Web of Science ®Google Scholar
• Zheng J, Xin Y, Zhang J, et al. (2018). Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos 46:237–47.
   PubMed Web of Science ®Google Scholar
• Zmarowski A, Beekhuijzen M, Lensen J, Emmen H. (2012). Differential performance of Wistar Han and Sprague Dawley rats in behavioral tests: differences in baseline behavior and reactivity to positive control agents. Reprod Toxicol 34:192–203.
   PubMed Web of Science ®Google Scholar